JNJ Q4 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Earnings

Johnson & Johnson closed out 2025 on a high note, reporting Q4 revenue of $24.56 billion, up 9.1% year-over-year and ahead of the $24.13 billion Wall Street had expected, while adjusted EPS of $2.46 matched consensus exactly, representing a 20.6% jum… Read more Johnson & Johnson closed out 2025 on a high note, reporting Q4 revenue of $24.56 billion, up 9.1% year-over-year and ahead of the $24.13 billion Wall Street had expected, while adjusted EPS of $2.46 matched consensus exactly, representing a 20.6% jump from the prior-year period. The standout driver was the Innovative Medicine segment, where oncology powerhouse DARZALEX surged 26.6% to $3.90 billion and TREMFYA soared 67.6% to $1.59 billion, more than offsetting a steep 47.7% decline in STELARA amid biosimilar pressure. MedTech contributed meaningfully as well, with cardiovascular sales climbing 11.5% to $2.30 billion, a gain that comes as J&J makes inroads in electrophysiology, adding competitive pressure on rivals in the pulsed field ablation space. Full-year sales reached $94.19 billion, and management is guiding for roughly $100.50 billion in 2026 revenue alongside adjusted EPS of $11.53, projections that reflect confidence in a diversified growth trajectory anchored by oncology momentum and a planned Orthopaedics separation.